Antibiotic policy in critical patients;Política de antibióticos en pacientes críticos

Medicina Intensiva

Volumn 34, Issue 9, 2010, Pages 600-608

  Alvarez Lerma F ^a   Sierra Camerino, R ^b   Alvarez Rocha L ^c   Rodriguez Colomo O ^d  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Antibiotic policy; Cycling of antibiotics; Preemptive treatment; Therapeutic de escalation

Indexed keywords

ANTIBIOTIC THERAPY; ARTICLE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG USE; HUMAN; MORBIDITY; PHARMACODYNAMICS; PHARMACOKINETICS; PRACTICE GUIDELINE;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG UTILIZATION; HUMANS;

EID: 78650183454     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2010.03.001     Document Type: Article

References (64)

1. Álvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in intensive care unit. Intensive Care Med 1996, 22:387-394. ICU-Adquired Pneumonia Study Group.
2. Luna C.L., Vujacich P., Niederman M.S., Vay C., Gherardi C., Matera J., et al. Impact of BAL data on the therapy ant outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
3. Kollef M.H. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
4. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
5. Rahal J.J., Urban C., Horn D., Freeman K., Segal-Maurer J., Mariano N., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 14:1233-1237.
6. Fridkin S.K., Edwards J.R., Tenover F.C., Gaynes R.P., McGowan J.E. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001, 33:324-330. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project; National Nosocomial Infections Surveillance (NNIS) System Hospitals.
7. Álvarez-Lerma F., Palomar M., Grau S. Management of antimicrobial use in the intensive care unit. Drugs 2001, 61:763-775.
8. Álvarez-Lerma F., Olaechea P., Grau S., Marín M., Domínguez A., Martínez-Lanao J., et al. Recomendaciones para la monitorizació;n de antibió;ticos en pacientes de la UCI. Enferm Infecc Microbiol Clin 2008, 26:230-239. Grupo de Estudio de Infecció;n en el paciente crítico (GEIPC-SEIMC).
9. Díaz E., Rello J. Top ten list in antibiotic policy in the ICU. Chest 2002, 122:712-714.
10. American College of Chest Physicians and Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
11. The problem of sepsis- an expert report of the European Society of Intensive Care Medicine. Intensive Care Med 1994, 20:300-304. European Society of Intensive Care Medicine.
12. Vandenbroucke-Grauls C.M.J.E., Vandenbroucke J.P. Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet 1991, 338:859-862.
13. Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. Selective Decontamination of the Digestive Tract Trialists' Collaborative Group. BMJ 1993, 307:525-532.
14. Kollef M.H. The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis. Chest 1994, 105:1101-1108.
15. Silvestri L., Van Saene H.K., Milanese M., Gregori D., Gullo A. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect 2007, 65:187-203.
16. Silvestri L., Van Saene H.K., Thomann C., Perić M. Selective decontamination of the digestive tract reduces pneumonia and mortality without resistance emerging. Am J Infect Control 2007, 35:354-357.
17. Sirvent J.M., Torres A., El-Ebiary M., Castro P., De Batlle J., Bonet A. Prospective effect of intravenously administered cefuroxime againts nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med 1997, 155:1729-1734.
18. Safdar N., Said A., Lucey M.R. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: A systematic review and meta-analysis. Liver Transpl 2004, 10:817-827.
19. Tetteroe G.W., Wagenvoort J.H., Castelein A., Tilanus H.W., Ince C., Bruining H.A. Selective decontamination to reduce gram-negative colonization and infections after aesophageal resection. Lancet 1990, 335:704-707.
20. Nathens A.B., Marshall J.C. Selective decontamination of digestive tract in surgical patients. A systematic review of the evidence. Arch Surg 1999, 134:170-176.
21. Pederzoli P., Bassi C., Vesentini S., Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993, 176:480-483.
22. Dellinger E.P., Tellado J.M., Soto N.E., Ashley S.W., Barie P.S., Dugernier T., et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: A randomized, double-blind, placebo-controlled study. Ann Surg 2007, 245:674-683.
23. Jorda R., Parras F., Ibañez J., Reina J., Bergadá J., Raurich J.M. Diagnosis of nosocomial pneumonia in mechanically ventilated patients by the blind protected telescoping catheter. Intensive Care Med 1993, 19:377-383.
24. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew P.D., Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143:1121-1129.
25. Sánchez Carrillo C, Guerrero Gó;mez C. Recogida, transporte y procesamiento general de muestras de laboratorio de Microbiología. En: Cercenado E, Cantó;n R. Procedimientos de Microbiología Clínica. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). 2003. [consultado 23/4/2010]. Disponible en: http://www.seimc.org/documentos/protocolos/microbiologia/.
26. Ribes J.A., Limper A.H., Espy M.J., Smith T.F. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: Analysis of sensitivity and specificity. J Clin Microbiol 1997, 35:830-835.
27. Sandhu G.S., Kline B.C., Stockman L., Roberts G.D. Molecular probes for diagnosis of fungal infections. J Clin Microbiol 1995, 33:2913-2919.
28. Coll P, Coque MT, Domínguez MA, Vázquez J, Vila J. Métodos moleculares de tipificació;n epidemioló;gica en bacteriología. En: Cercenado E, Cantó;n R. Procedimientos de Microbiología Clínica. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). 2005. [consultado 23/4/2010]. Disponible en: http://www.seimc.org/documentos/protocolos/microbiologia/.
29. Fink M.P., Snydman D.R., Niederman M.S., Leeper K.V., Johnson R.H., Heard S.O., et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with impipenem-cilastatin. Antimicrob Agents Chemother 1994, 38:547-557.
30. Menéndez R., Perpiñá M., Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003, 18:103-111.
31. Pea F., Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: Focus on drug interactions. Clin Pharmacokinet 2001, 40:833-868.
32. Foxworth J. Recognizing and preventing antibiotic-associated complications in the critical care setting. Crit Care Nurs Q 1997, 20:1-11.
33. Joannidis M. Drug-induced renal failure in the ICU. Int J Artif Organs 2004, 27:1034-1042.
34. Debord J., Voultoury J.C., Lachatre G., Favereau J.P., Gay R. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients. Int J Biomed Comput 1994, 36:135-137.
35. Dworzak D.L., Pugsley M.P., Sanders C.L., Horowitt E.A. Emergence of resistance in Gram-negative bacteria during therapy with extended-spectrum cephalosporin. Eur J Clin Microbiol 1987, 6:456-459.
36. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among Gram-negative bacilli in US Intensive Care Units. Implications for fluoroquinolone use. JAMA 2003, 289:885-888.
37. Akinci E., Colpan A., Bodur H., Balaban N., Hervía A. Risk factors for ICU-acquired imipenem-resistant gram-negative bacterial infections. J Hosp Infect 2005, 59:317-323.
38. Meyer E., Schwab F., Gastmeier P., Rueden H., Daschner F.D., Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: Data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units. J Hosp Infect 2006, 64:238-243.
39. Chastre J., Wolff M., Fagon J.Y., Chevret S., Thomas F., Wermert D. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
40. Kollef M.H. Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med 2001, 29:1473-1475.
41. Ibrahim E.H., Ward S., Sherman G., Schaiff R., Fraser V.J., Kollef M.H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115.
42. Rello J., Vidaur L., Sandiumenge A., Rodríguez A., Gualis B., Boque C., et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004, 32:2183-2190.
43. Álvarez-Lerma F., Álvarez B., Luque P., Ruiz F., Domínguez-Roldán J.M., Quintana E., et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: A prospective observational study. Crit Care 2006, 10:R78.
44. Leone M., Garcin F., Bouvenot J., Boyadjev I., Visintini P., Albanèse J., et al. Ventilator-associated pneumonia: Breaking the vicious circle of antibiotic overuse. Crit Care Med 2007, 35:379-385.
45. Giantsou E., Liratzopoulos N., Efraimidou E., Panopoulou M., Alepopoulou E., Kartali-Ktenidou S., et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007, 33:1533-1540.
46. Gerding D.N., Larson T.A., Hughes R.A., Weiler M., Shanholtzer C., Peterson L.R. Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital. Antimicrob Agents Chemother 1991, 35:1284-1290.
47. Kollef M.H., Vlasnik J., Sharpless L., Pasque C., Murphy D., Fraser V. Scheduled change of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:1040-1048.
48. Gruson D., Hibert G., Vargas F., Valentino R., Bebear C., Allery A., et al. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000, 162:837-843.
49. Hughes M.G., Evans H.L., Chong T.W., Smith R.L., Raymond D.P., Pelletier S.J., et al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 2004, 32:53-60.
50. Merz L.R., Warren D.K., Kollef M.H., Fraser V.J. Effects of an antibiotic cycling program on antibiotic prescribing practices in an intensive care unit. Anitmicrob Agents Chemother 2004, 48:2861-2865.
51. Martínez J.A., Nicolás J.M., Marco F., Horcajada J.P., García-Segarra G., Trilla A., et al. Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 2006, 34:329-336.
52. Sandiumenge A., Díaz E., Rodríguez A., Vidaur L., Canadell L., Olona M., et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006, 57:1197-1204.
53. Brown E., Nathwani D. Antibiotic cycling or rotation: A systematic review of the evidence of efficacy. J Antimicrob Chemother 2005, 55:6-9.
54. Masterton R.G. Antibiotic cycling: more than it might seem?. J Antimicrob Chemother 2005, 55:1-5.
55. Kollef M.H. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the Intensive Care Unit?. Clin Infect Dis 2006, 43:S82-S88.
56. Maertens J., Theunissen K., Verhoef G., Verschakelen J., Lagrou K., Verbeken E., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005, 41:1242-1250.
57. Pittet D., Monod M., Suter P.M., Frenk E., Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758.
58. Leó;n C., Ruiz-Santana S., Saavedra P., Almirante B., Nolla-Salas J., Álvarez-Lerma F., et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737.
59. Blondeu J.M., Hansen G., Metzler K., Hedlin P. The role of PK/PD parameters to avoid and increase of resistance: Mutant prevention concentration. J Chemother 2004, 16:1-19.
60. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998, 279:159-160.
61. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M., Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-1081.
62. Thomas J.K., Forrest A., Bhavnani S.M., Hyatt J.M., Cheng A., Ballow C.H. Pharmacodynamic evaluation of factors associated with development of bacteria resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42:521-527.
63. Pea F., Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: Focus on drug interactions. Clin Pharmacokinet 2001, 40:833-868.
64. Grau S., Álvarez-Lerma F., Domínguez-Gil A. Pharmacokinetic/pharmacodynamic indices: Are we ready to use them in daily practice?. Expert Rev Anti Infect Ther 2007, 5:913-916.